7 Reasons Your Doctor Hesitates to Prescribe Testosterone

Last verified: July 25, 2026. This article is educational and is not personal medical advice. Testosterone therapy decisions should be made with a clinician who can review symptoms, lab results, medications, prostate history, blood counts, cardiovascular risk, and clotting history.

A common visit now starts with a reasonable question: “If the FDA removed the big heart-risk warning, why is my doctor still hesitant to prescribe testosterone?” The short answer is that the old heart-attack-and-stroke worry has changed, but it has not turned testosterone replacement therapy into a quick anti-aging prescription. In 2026, doctors’ concerns about testosterone replacement in older patients usually fall into seven separate checks: cardiovascular events, atrial fibrillation and blood pressure, prostate monitoring, erythrocytosis, pulmonary embolism, diagnostic certainty, and expectations about what TRT can and cannot fix.

That distinction matters. A doctor who still says, flatly, “testosterone is dangerous for the heart,” without acknowledging the newer evidence is giving an incomplete explanation. A doctor who says, “The heart-attack question is less worrisome than it used to be, but I still need two proper morning tests and a monitoring plan,” is usually practicing careful medicine.

The heart warning changed, but the visit still has to slow down

For years, cardiovascular risk dominated the testosterone conversation. That fear was not imaginary. In 2015, the FDA required labeling changes and warned about possible increased risk of heart attack and stroke with testosterone products. Then came TRAVERSE, the trial doctors had been waiting for.

TRAVERSE enrolled 5,246 men, ages 45 to 80, with symptoms of hypogonadism, confirmed low testosterone, and either existing cardiovascular disease or high cardiovascular risk. The mean age was 63. For major adverse cardiovascular events — cardiovascular death, nonfatal heart attack, or nonfatal stroke — testosterone gel was noninferior to placebo, with a hazard ratio of 0.96 and a 95% confidence interval of 0.78 to 1.17.[1]

In plain clinic language: in the kind of men TRAVERSE studied, testosterone did not raise the main combined risk of heart attack, stroke, or cardiovascular death compared with placebo during the trial’s follow-up. That is a major change from the uncertainty that hung over prescribing for a decade.

The FDA responded in February 2025 by removing the boxed warning about myocardial infarction and stroke from testosterone product labeling. At the same time, it added a class-wide warning about increased blood pressure based on ambulatory blood pressure monitoring studies.[2]

That is why the cardiovascular checkpoint is not “TRT is forbidden.” It is more precise: does this patient resemble the men who were studied, and are the remaining cardiovascular signals being watched? TRAVERSE does not tell us everything about healthier men, men over 80, or treatment continued for many years. It also had a mean treatment duration of about 22 months, and the broader evidence base still leaves limited safety data beyond four years.[1]

Seven concerns your doctor is sorting through

1. Heart attack and stroke: the old fear is not the same concern anymore

This is the checkpoint that has changed the most. Before TRAVERSE, a cautious doctor could reasonably worry that testosterone might increase heart attack or stroke risk in older men with cardiovascular disease. After TRAVERSE, that broad worry is harder to defend for men who match the trial population and are treated to appropriate testosterone levels.

But the trial did not study “any older man who feels tired.” It studied men with symptoms, confirmed low testosterone, and cardiovascular disease or high cardiovascular risk. It also did not settle the question for men above 80, who are often the patients whose families most want a clear yes or no. A clinician may be reassured and still unwilling to skip the workup.

2. Atrial fibrillation and blood pressure: the quieter cardiovascular issues remain

TRAVERSE did not close every cardiovascular file. Atrial fibrillation occurred in 3.5% of men assigned to testosterone and 2.4% of men assigned to placebo. The systolic blood pressure shift reported in the trial was small, about +0.3 mmHg, but the FDA’s 2025 labeling action added a class-wide warning about increased blood pressure based on ambulatory blood pressure monitoring studies.[1][2]

That is why an older patient may be asked about palpitations, prior rhythm problems, stroke history, sleep apnea, blood pressure readings, and home monitoring before a prescription is written. None of that means the doctor is ignoring the FDA’s removal of the boxed warning. It means the doctor has moved from the old broad fear to the risks still left on the chart.

3. Prostate concerns: less alarming than many men fear, not finished

The prostate question is another place where older fear and current evidence need to be separated. In TRAVERSE, there was no excess prostate cancer signal during the available follow-up. PSA rose modestly: 0.20 ± 0.61 ng/mL in the testosterone group versus 0.08 ± 0.90 ng/mL in the placebo group.[1]

That is reassuring, but it is not a lifetime guarantee. The Endocrine Society’s July 2026 statement called for a “Men’s Health Initiative” analogous to the Women’s Health Initiative to study long-term effects of testosterone therapy, including questions that short and medium-term trials cannot settle.[3]

In practice, this means a doctor should not use prostate risk as a vague scare tactic. It also means PSA history, urinary symptoms, prior prostate cancer evaluation, and follow-up PSA monitoring are not optional details.

4. Erythrocytosis: common, dose-related, and usually manageable if someone is watching

Erythrocytosis means the red blood cell concentration rises too high. The number clinicians watch is hematocrit. This is one of the most practical reasons a careful doctor pauses before starting TRT: not because it is mysterious, but because it requires follow-up.

The American Urological Association guideline identifies hematocrit elevation above 54% as an important threshold during testosterone therapy. Erythrocytosis is a known dose-related adverse effect and is especially associated with injectable formulations; monitoring every 3 to 6 months in the first year is standard practice.[4]

This is not a reason to frighten a man away from treatment if he truly has hypogonadism. It is a reason not to prescribe testosterone as though the visit ends when the prescription is signed. If the hematocrit climbs, the dose, formulation, interval, or treatment plan may need to change.

5. Pulmonary embolism: less common, but serious enough to ask about

Pulmonary embolism is a blood clot that travels to the lungs. In TRAVERSE, pulmonary embolism occurred in 0.9% of men in the testosterone group and 0.5% of men in the placebo group.[1]

That is not a high-frequency event, but it is a serious one. A patient with a prior clot, known clotting disorder, recent immobility, active cancer, or unexplained swelling and shortness of breath history deserves a more careful discussion than a man without those factors. The point is not to make every older man afraid of a rare outcome. The point is to avoid pretending the only cardiovascular question was heart attack and stroke.

The diagnosis is often where the TRT conversation goes wrong

Many disappointing testosterone visits begin before the first risk is discussed. The patient has fatigue, less muscle, belly weight, lower libido, or a flatter mood. Those symptoms are real. They are also not specific. Poor sleep, depression, alcohol use, medication effects, thyroid disease, anemia, chronic pain, diabetes, grief, and deconditioning can all sit in the same chair wearing the same complaint.

The Endocrine Society’s July 2026 statement emphasized proper diagnosis and called for two morning fasting total testosterone tests below 300 ng/dL before diagnosing testosterone deficiency. It also warned that labels such as “age-related” or “functional” hypogonadism can blur the line between disease and normal aging.[3]

That is not a technicality. Testosterone levels vary during the day and from one test to another. A single afternoon result, or a borderline number without matching symptoms, should not carry the weight of a long-term hormone decision. FDA data from 2011, analyzed in a 2017 study, found that about 20% of men prescribed testosterone did not meet laboratory criteria.[5]

A useful appointment question is simple: “Have I had two low morning testosterone tests, and do my symptoms fit hypogonadism?” If the answer is no, the next step may be better testing rather than an argument about whether TRT is good or bad.

Lifestyle is not a scolding substitute for treatment

Some men hear “lose weight and exercise” as dismissal. It should not be used that way. A man who feels older, weaker, and less sexual does not need a lecture. He needs a clinician to decide whether hormone replacement is treating a medical deficiency or being asked to do the work of sleep repair, strength training, weight loss, medication review, and chronic disease management.

For men with BMI above 27 and obesity-associated low testosterone, the Endocrine Society emphasizes weight loss and exercise as first-line therapy before long-term testosterone replacement.[3]

This is also where expectations need to be honest. TRT is not a guaranteed fix for every symptom attached to aging. If treatment is stopped, recovery of natural testosterone production may take 3 to 6 months.[6] That does not mean no one should start. It means the patient should know what kind of commitment is being made.

For the muscle-strength side of the discussion, it can help to separate hormone deficiency from ordinary muscle preservation strategies, including resistance training and cautious review of products marketed for aging muscle. See CareWise Guide’s discussion of whether supplements for aging muscle repair and strength work for a related but separate question.

Regulatory changes do not remove the prescribing decision

The regulatory landscape is moving. In June 2026, HHS proposed that the FDA remove the “limitation of use” language for age-related hypogonadism, but that proposal was not final as of this article’s verification date.[7] AARP also reported in July 2026 that testosterone prescriptions dropped about 50% after the 2015 warning and that newer changes may trigger a rebound in interest.[6]

A rebound in interest is not the same as a broader proven benefit. Testosterone products remain FDA-approved for hypogonadism due to a medical condition. Using testosterone mainly for aging-related symptoms remains an individual clinical decision, and it should not be made with advertising language in place of diagnostic evidence.

What a careful TRT conversation should include

If a doctor simply refuses and says, “It is too dangerous,” the patient is entitled to ask for a clearer explanation. If a patient arrives assuming the FDA label change means caution is obsolete, the doctor is entitled to slow the visit down. The productive middle is a checklist, not a slogan.

• Have there been two low morning fasting total testosterone results, not just one convenient test?
• Do the symptoms fit testosterone deficiency, or are there other likely causes that have not been checked?
• What are the baseline hematocrit, PSA, blood pressure, cardiovascular history, rhythm history, and clot history?
• Which formulation is being considered, and how will dose-related erythrocytosis be monitored?
• When will labs and symptoms be reassessed, and what result would lead to stopping or changing therapy?
• What should the patient expect if TRT is stopped after several months or years?

By 2026, the main heart-attack-and-stroke concern has been substantially answered for the TRAVERSE population. Atrial fibrillation, blood pressure, erythrocytosis, pulmonary embolism, prostate monitoring, diagnostic looseness, and inflated expectations remain real reasons for a careful physician to hesitate before prescribing.

The most useful question is not “Will my doctor prescribe testosterone?” It is: “Can we walk through the reasons for or against it in my case, using proper tests and a monitoring plan?”

References

1. Cardiovascular Safety of Testosterone-Replacement Therapy, N Engl J Med, 2023, link
2. FDA class-wide labeling changes for testosterone products, FDA, February 28, 2025, link
3. Endocrine Society Statement on TRT, Endocrine Society, July 2026, link
4. Testosterone Deficiency Guideline, American Urological Association, link
5. Trends in Testosterone Prescribing and Testing From 2011-2015 in the United States, Eur Urol Focus, 2017, link
6. Testosterone Therapy Changes for Men over 50, AARP, July 2026, link
7. Requested Updates to Testosterone Therapy Labeling, HHS, June 2026, link